RU2504550C2 - Длительно действующие агонисты рецепторов y2 и(или) y4 - Google Patents
Длительно действующие агонисты рецепторов y2 и(или) y4 Download PDFInfo
- Publication number
- RU2504550C2 RU2504550C2 RU2010149474/04A RU2010149474A RU2504550C2 RU 2504550 C2 RU2504550 C2 RU 2504550C2 RU 2010149474/04 A RU2010149474/04 A RU 2010149474/04A RU 2010149474 A RU2010149474 A RU 2010149474A RU 2504550 C2 RU2504550 C2 RU 2504550C2
- Authority
- RU
- Russia
- Prior art keywords
- ethoxy
- acetylamino
- acetyl
- seq
- butyrylamino
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 4
- 102000007562 Serum Albumin Human genes 0.000 claims abstract 3
- 108010071390 Serum Albumin Proteins 0.000 claims abstract 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 94
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 72
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 claims 58
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 claims 47
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 47
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 claims 43
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 43
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 40
- 108010088847 Peptide YY Proteins 0.000 claims 31
- -1 Val Chemical compound 0.000 claims 31
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 29
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 29
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 29
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 29
- 229960003104 ornithine Drugs 0.000 claims 29
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 claims 11
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 claims 11
- 229940124277 aminobutyric acid Drugs 0.000 claims 11
- FMUMEWVNYMUECA-LURJTMIESA-N (2s)-2-azaniumyl-5-methylhexanoate Chemical compound CC(C)CC[C@H](N)C(O)=O FMUMEWVNYMUECA-LURJTMIESA-N 0.000 claims 10
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 10
- WTKYBFQVZPCGAO-LURJTMIESA-N (2s)-2-(pyridin-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CN=C1 WTKYBFQVZPCGAO-LURJTMIESA-N 0.000 claims 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 5
- 102000005962 receptors Human genes 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 4
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 101000585528 Homo sapiens Peptide YY Proteins 0.000 claims 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- 102100038991 Neuropeptide Y receptor type 2 Human genes 0.000 claims 2
- 101710197945 Neuropeptide Y receptor type 2 Proteins 0.000 claims 2
- 102000028435 Neuropeptide Y4 receptor Human genes 0.000 claims 2
- 108010002245 Neuropeptide Y4 receptor Proteins 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 2
- 229960002591 hydroxyproline Drugs 0.000 claims 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 claims 1
- 101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 claims 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- 125000000205 L-threonino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])[C@](C([H])([H])[H])([H])O[H] 0.000 claims 1
- 101150118523 LYS4 gene Proteins 0.000 claims 1
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 claims 1
- 101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 claims 1
- VNYDHJARLHNEGA-RYUDHWBXSA-N Tyr-Pro Chemical group C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 VNYDHJARLHNEGA-RYUDHWBXSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 108010020532 tyrosyl-proline Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract 2
- 125000002843 carboxylic acid group Chemical group 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 0 CC(CCCCCCCCCCCCCCCCC(NC(CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@](C(P)=O)N*)=O)=O)=O)C(O)=O)=O)=C Chemical compound CC(CCCCCCCCCCCCCCCCC(NC(CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@](C(P)=O)N*)=O)=O)=O)C(O)=O)=O)=C 0.000 description 2
- HXDOZKJGKXYMEW-UHFFFAOYSA-N CCc(cc1)ccc1O Chemical compound CCc(cc1)ccc1O HXDOZKJGKXYMEW-UHFFFAOYSA-N 0.000 description 1
- IWDCLRJOBJJRNH-UHFFFAOYSA-N Cc(cc1)ccc1O Chemical compound Cc(cc1)ccc1O IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08156360 | 2008-05-16 | ||
| EP08156360.3 | 2008-05-16 | ||
| EP09154461 | 2009-03-05 | ||
| EP09154461.9 | 2009-03-05 | ||
| PCT/EP2009/055989 WO2009138511A1 (en) | 2008-05-16 | 2009-05-18 | Long-acting y2 and/or y4 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010149474A RU2010149474A (ru) | 2012-06-27 |
| RU2504550C2 true RU2504550C2 (ru) | 2014-01-20 |
Family
ID=40934036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010149474/04A RU2504550C2 (ru) | 2008-05-16 | 2009-05-18 | Длительно действующие агонисты рецепторов y2 и(или) y4 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110275559A1 (https=) |
| EP (1) | EP2279204A1 (https=) |
| JP (1) | JP2011520847A (https=) |
| KR (1) | KR20110017874A (https=) |
| CN (1) | CN102027007A (https=) |
| AU (1) | AU2009248041B2 (https=) |
| BR (1) | BRPI0912615A2 (https=) |
| CA (1) | CA2723855A1 (https=) |
| IL (1) | IL208836A0 (https=) |
| MX (1) | MX2010011845A (https=) |
| RU (1) | RU2504550C2 (https=) |
| WO (1) | WO2009138511A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2678312C1 (ru) * | 2013-11-15 | 2019-01-25 | Ново Нордиск А/С | Селективные соединения пептида yy и их применения |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9260500B2 (en) | 2009-07-02 | 2016-02-16 | Takeda Pharmaceutical Company Limited | Peptide and use thereof |
| EP2477643A1 (en) * | 2009-09-18 | 2012-07-25 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| WO2011058165A1 (en) * | 2009-11-13 | 2011-05-19 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| GB201001333D0 (en) * | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| EP2600887A4 (en) | 2010-07-09 | 2014-01-22 | Amylin Pharmaceuticals Llc | MICROCRYSTALLINE Y RECEPTOR AGONISTS |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| CN104203266B (zh) | 2012-03-22 | 2017-12-26 | 诺和诺德股份有限公司 | Glp‑1肽组合物及其制备 |
| JP6672140B2 (ja) | 2013-05-02 | 2020-03-25 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１化合物の経口投薬 |
| EP2842965A1 (en) | 2013-09-03 | 2015-03-04 | Gubra ApS | Neuromedin U analogs comprising serum albumin binding amino acid residue |
| US10583172B2 (en) | 2013-11-15 | 2020-03-10 | Novo Nordisk A/S | HPYY(1-36) having a beta-homoarginine substitution at position 35 |
| WO2015073878A1 (en) * | 2013-11-15 | 2015-05-21 | Ur Diet, Llc | Real-time satiety biofeedback |
| MX369818B (es) | 2013-11-15 | 2019-11-22 | Novo Nordisk As | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. |
| US20240100450A9 (en) * | 2014-01-17 | 2024-03-28 | Repligen Corporation | Sterilizing chromatography columns |
| US10610807B2 (en) | 2014-01-17 | 2020-04-07 | Repligen Corporation | Sterilizing chromatography columns |
| CN114805527A (zh) * | 2014-05-21 | 2022-07-29 | 哈佛大学的校长及成员们 | Ras抑制肽和其用途 |
| MA43205A (fr) | 2015-06-12 | 2018-09-19 | Novo Nordisk As | Composés pyy sélectifs et leurs utilisations |
| PL3746111T3 (pl) | 2018-02-02 | 2024-01-15 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową |
| TWI749381B (zh) * | 2018-11-01 | 2021-12-11 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
| GB201908426D0 (en) * | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Appetite suppressing compounds |
| AU2021257477A1 (en) * | 2020-04-17 | 2022-12-08 | I2O Therapeutics, Inc. | Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use |
| CA3215858A1 (en) | 2021-04-27 | 2022-11-03 | Zhenhuan ZHENG | Combination of bitter receptor agonist and gut-signaling compound |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005027978A2 (en) * | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| WO2005077094A2 (en) * | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Pancreatic polypeptide family motifs and polypeptides comprising the same |
| WO2005089786A2 (en) * | 2004-03-17 | 2005-09-29 | 7Tm Pharma A/S | Y4 selective receptor agonists for therapeutic interventions |
| WO2006005667A2 (en) * | 2004-07-08 | 2006-01-19 | Novo Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
| RU2275207C2 (ru) * | 2000-12-14 | 2006-04-27 | Амилин Фармасьютикалз, Инк. | Способ снижения доступности питательного вещества, способ подавления аппетита |
| WO2007009894A2 (en) * | 2005-07-18 | 2007-01-25 | Novo Nordisk A/S | Peptides for use in the treatment of obesity |
-
2009
- 2009-05-18 CN CN2009801173043A patent/CN102027007A/zh not_active Withdrawn
- 2009-05-18 AU AU2009248041A patent/AU2009248041B2/en not_active Ceased
- 2009-05-18 KR KR1020107027495A patent/KR20110017874A/ko not_active Withdrawn
- 2009-05-18 MX MX2010011845A patent/MX2010011845A/es not_active Application Discontinuation
- 2009-05-18 EP EP09745843A patent/EP2279204A1/en not_active Withdrawn
- 2009-05-18 RU RU2010149474/04A patent/RU2504550C2/ru not_active IP Right Cessation
- 2009-05-18 CA CA2723855A patent/CA2723855A1/en not_active Withdrawn
- 2009-05-18 WO PCT/EP2009/055989 patent/WO2009138511A1/en not_active Ceased
- 2009-05-18 BR BRPI0912615A patent/BRPI0912615A2/pt not_active Application Discontinuation
- 2009-05-18 US US12/993,015 patent/US20110275559A1/en not_active Abandoned
- 2009-05-18 JP JP2011508945A patent/JP2011520847A/ja not_active Withdrawn
-
2010
- 2010-10-20 IL IL208836A patent/IL208836A0/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2275207C2 (ru) * | 2000-12-14 | 2006-04-27 | Амилин Фармасьютикалз, Инк. | Способ снижения доступности питательного вещества, способ подавления аппетита |
| WO2005027978A2 (en) * | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| WO2005077094A2 (en) * | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Pancreatic polypeptide family motifs and polypeptides comprising the same |
| WO2005089786A2 (en) * | 2004-03-17 | 2005-09-29 | 7Tm Pharma A/S | Y4 selective receptor agonists for therapeutic interventions |
| WO2006005667A2 (en) * | 2004-07-08 | 2006-01-19 | Novo Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
| WO2007009894A2 (en) * | 2005-07-18 | 2007-01-25 | Novo Nordisk A/S | Peptides for use in the treatment of obesity |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2678312C1 (ru) * | 2013-11-15 | 2019-01-25 | Ново Нордиск А/С | Селективные соединения пептида yy и их применения |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010011845A (es) | 2010-11-22 |
| BRPI0912615A2 (pt) | 2016-01-26 |
| CA2723855A1 (en) | 2009-11-19 |
| EP2279204A1 (en) | 2011-02-02 |
| RU2010149474A (ru) | 2012-06-27 |
| WO2009138511A1 (en) | 2009-11-19 |
| JP2011520847A (ja) | 2011-07-21 |
| CN102027007A (zh) | 2011-04-20 |
| KR20110017874A (ko) | 2011-02-22 |
| AU2009248041B2 (en) | 2013-10-03 |
| IL208836A0 (en) | 2011-01-31 |
| AU2009248041A1 (en) | 2009-11-19 |
| US20110275559A1 (en) | 2011-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2504550C2 (ru) | Длительно действующие агонисты рецепторов y2 и(или) y4 | |
| JP2011520847A5 (https=) | ||
| AU2014241743B2 (en) | Insulin-incretin conjugates | |
| FI120586B (fi) | Menetelmä PTH:n ja PTHRP:n analogien valmistamiseksi, ja niiden käyttö osteoporoosin hoitoon | |
| JP2016512213A5 (https=) | ||
| JP5887265B2 (ja) | Ｇｉｐ受容体活性グルカゴン化合物 | |
| JP2010538049A5 (https=) | ||
| CN103957927B (zh) | 呈现糖皮质激素受体活性的胰高血糖素超家族肽 | |
| AU2010216372B2 (en) | Cytotoxic conjugates having neuropeptide Y receptor binding compound | |
| JP5606314B2 (ja) | Ａ−ｂ−ｃ−ｄ−で誘導体化されたペプチドとその治療用途 | |
| JP2014502252A5 (https=) | ||
| JP2011502155A5 (https=) | ||
| CN108271356A (zh) | 肠降血糖素-胰岛素缀合物 | |
| WO2010111617A4 (en) | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use | |
| JP2018505146A5 (https=) | ||
| JP2012529463A5 (https=) | ||
| US20180265560A1 (en) | Biphasic single-chain insulin analogues | |
| AR071990A1 (es) | Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto | |
| WO2008118017A3 (en) | Prame derived peptides and immunogenic compositions comprising these | |
| TW201010730A (en) | Glucagon analogs exhibiting enhanced solubility and stability in physiological PH buffers | |
| JP2012518035A5 (https=) | ||
| CA2755133A1 (en) | Selective and potent peptide inhibitors of kv1.3 | |
| JP2011509088A (ja) | 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体 | |
| US20220002373A1 (en) | Single-chain insulin analogues with poly-alanine c-domain sub-segments | |
| JP2002509854A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150519 |